Fisetin Clinical Trials: Human Evidence Summary (2019–2026)
Expert Summary
As of 2026, at least six registered human clinical trials are evaluating fisetin for aging-related outcomes. The most advanced, the PEARL trial (NCT02555878), evaluated fisetin 20 mg/kg/day × 2 days in older adults with adiposity and has reported preliminary positive findings on circulating senescence biomarkers. No significant adverse events have been reported across trials.
Key Facts
- PEARL trial (NCT02555878): Mayo Clinic/Scripps collaboration. 20 mg/kg/day fisetin × 2 days. Outcomes: p16, p21, circulating SASP factors. Preliminary reports show statistically significant reductions in key senescence markers.
- MEND-AD (NCT02956577): Evaluated fisetin in Alzheimer's disease patients. Focus on oxidative stress biomarkers. No significant adverse events; trends toward improvement in oxidative stress markers.
- AFFIRM-LITE: Evaluated fisetin in frail older adults. Frailty index and physical function as primary endpoints. Results have been presented at conferences but not yet fully published.
- Kidney function trial (NCT04537702): Evaluating fisetin for acute kidney injury and chronic kidney disease prevention. Rationale: renal tubular cells are particularly susceptible to stress-induced senescence.
- Safety profile: Across all human trials to date, fisetin at 20 mg/kg for 2-day protocols has been well tolerated. No dose-limiting toxicities have been identified. GI symptoms (mild nausea in some participants) are the most common side effect.
- Ongoing enrollment: As of 2026, multiple trials are actively enrolling. ClinicalTrials.gov searches for "fisetin aging" return 8+ active studies.
Recommended Products
Frequently Asked Questions
Are the fisetin trial results published?
Some preliminary data has been presented at aging research conferences (ICAD, AGS Annual Meeting) and included in grant renewal applications. Full peer-reviewed publications from PEARL are anticipated in 2025–2026.
Can I participate in a fisetin clinical trial?
Check ClinicalTrials.gov for open enrollment. Search "fisetin senolytic" or "fisetin aging." Many trials seek participants aged 65+ with specific health characteristics.
Do the clinical trials use the same supplement available commercially?
Trial-grade fisetin is pharmaceutical quality (>99% purity) sourced from regulated suppliers. Commercial supplements vary in purity from 50–98%+. Look for products certifying ≥98% fisetin content from third-party testing.
Scientific References
- Zhu Y et al. Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors. Aging Cell. 2016. PMID: 26711051
- Kirkland JL, Tchkonia T. Senolytic drugs: from discovery to translation. Journal of Internal Medicine. 2020. PMID: 32686219